Answers are grounded in this paper and cite their sources.
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality, with limited treatment options and extremely poor prognoses. PANoptosis, an inflammatory programmed cell death mechanism integrating key features of apoptosis, pyroptosis, and necroptosis, demonstrates remarkable therapeutic potential through its unique “dual-pronged” mechanism that combines direct tumor cell elimination with robust antitumor immune activation. Capitalizing on the critical regulatory role of intracellular copper and zinc homeostasis in tumor progression and the distinctive copper/zinc enrichment characteristics in NSCLC tissues, this study innovatively develops a redox-responsive nanoplatform, TPEN@mPEG 2000 -SS-C 18 (TPEN@PSC), which pioneers a triple cascade therapeutic modality of “zinc/copper chelation-PANoptosis activation-cancer cells elimination/immune remodeling”. Mechanistic investigations reveal that TPEN@PSC induces zinc/copper chelation, driven ROS burst, DNA damage, and ER stress, activating PANoptosis. Concurrently, PANoptosis-released damage-associated molecular patterns promote dendritic cells maturation, M1 macrophage polarization, and CD8 + T/NK cell infiltration, converting “cold” tumors to an immunologically “hot” phenotype. In vivo , TPEN@PSC inhibits primary tumors with low toxicity and synergizes with anti-PD-1 to amplify antitumor immunity, establishing immune memory against rechallenge and lung metastasis. This transformative therapeutic strategy, which drives cancer cells PANoptosis through metal ion chelation, not only addresses the inherent limitations of conventional therapies but also pioneers a novel paradigm for zinc/copper-enriched malignancies.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: